Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

A Probiotic Preparation Duolac-Gold Ameliorates Dextran Sulphate Sodium-induced Mouse Colitis by Downregulating the Expression of IL-6

  • Received : 2014.01.28
  • Accepted : 2014.03.19
  • Published : 2014.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Probiotics are live microorganisms that confer a health benefit on the host. Duolac-Gold is a mixture of seven probiotic bacteria containing three species of Bifidobacteria, two species of Lactobacillus, and Streptococcus thermophilus. The aim of this study was to assess the anti-inflammatory effects of Duolac-Gold in an inflammatory bowel disease (IBD) mouse model. IBD was induced by administering 1.5% dextran sulfate sodium (DSS) for 10 days. After induction of DSS-induced colitis, Duolac-Gold was orally administered at three different concentrations. Interestingly, Duolac-Gold treatment accelerated IBD healing, and anti-inflammatory activity was assessed by weight loss, length of the colon, and a microscopic damage score by histology. The expression of inflammatory related cytokines was measured in colon tissues and serum. Of these cytokines, the expression of interleukin-6 decreased remarkably after Duolac-Gold treatment. Taken together, these results suggest that Duolac-Gold treatment is effective in IBD healing by regulating IL-6.

Keywords

References

  1. Bai, A.P. and Ouyang, Q. (2006) Probiotics and inflammatory bowel diseases. Postgrad. Med. J., 82, 376-382. https://doi.org/10.1136/pgmj.2005.040899
  2. Stein, J., Hartmann, F. and Dignass, A.U. (2010) Diagnosis and management of iron deficiency anemia in patients with IBD. Nat. Rev. Gastroenterol. Hepatol., 7, 599-610. https://doi.org/10.1038/nrgastro.2010.151
  3. Kaser, A., Zeissig, S. and Blumberg, R.S. (2010) Inflammatory bowel disease. Annu. Rev. Immunol., 28, 573-621. https://doi.org/10.1146/annurev-immunol-030409-101225
  4. Rogler, G. and Andus, T. (1998) Cytokines in inflammatory bowel disease. World J. Surg., 22, 382-389. https://doi.org/10.1007/s002689900401
  5. Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., Schutz, M., Bartsch, B., Holtmann, M., Becker, C., Strand, D., Czaja, J., Schlaak, J.F., Lehr, H.A., Autschbach, F., Schurmann, G., Nishimoto, N., Yoshizaki, K., Ito, H., Kishimoto, T., Galle, P.R., Rose-John, S. and Neurath, M.F. (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med., 6, 583-588. https://doi.org/10.1038/75068
  6. Shen, D., Liu, C., Xu, R. and Zhang, F. (2012) Human gut microbiota: dysbiosis and manipulation. Front. Cell. Infect. Microbiol., 2, 123.
  7. de Vos, W.M. and de Vos, E.A. (2012) Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr. Rev., 70 Suppl 1, S45-56. https://doi.org/10.1111/j.1753-4887.2012.00505.x
  8. Abraham, C. and Medzhitov, R. (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology, 140, 1729-1737. https://doi.org/10.1053/j.gastro.2011.02.012
  9. Bien, J., Palagani, V. and Bozko, P. (2013) The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther. Adv. Gastroenterol., 6, 53-68. https://doi.org/10.1177/1756283X12454590
  10. Walker, A.W. and Lawley, T.D. (2013) Therapeutic modulation of intestinal dysbiosis. Pharmacol. Res., 69, 75-86. https://doi.org/10.1016/j.phrs.2012.09.008
  11. Uccello, M., Malaguarnera, G., Basile, F., D'Agata, V., Malaguarnera, M., Bertino, G., Vacante, M., Drago, F. and Biondi, A. (2012) Potential role of probiotics on colorectal cancer prevention. BMC Surg., 12 Suppl 1, S35. https://doi.org/10.1186/1471-2482-12-S1-S35
  12. Ouwehand, A.C., Salminen, S. and Isolauri, E. (2002) Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek, 82, 279-289. https://doi.org/10.1023/A:1020620607611
  13. Salminen, S., Bouley, C., Boutron-Ruault, M.C., Cummings, J.H., Franck, A., Gibson, G.R., Isolauri, E., Moreau, M.C., Roberfroid, M. and Rowland, I. (1998) Functional food science and gastrointestinal physiology and function. Br. J. Nutr., 80 Suppl 1, S147-171. https://doi.org/10.1079/BJN19980108
  14. Sang, L.X., Chang, B., Zhang, W.L., Wu, X.M., Li, X.H. and Jiang, M. (2010) Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-analysis. World J. Gastroenterol., 16, 1908-1915. https://doi.org/10.3748/wjg.v16.i15.1908
  15. Lee, J.S., Chung, M.J. and Seo, J.G. (2013) In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile. Toxicol. Res., 29, 99-106. https://doi.org/10.5487/TR.2013.29.2.099
  16. Miyauchi, E., Ogita, T., Miyamoto, J., Kawamoto, S., Morita, H., Ohno, H., Suzuki, T. and Tanabe, S. (2013) Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PLoS One, 8, e79735. https://doi.org/10.1371/journal.pone.0079735
  17. Matsumoto, Y. (2005) New approach to immunotherapy against organ-specific autoimmune diseases with T cell receptor and chemokine receptor DNA vaccines. Curr. Drug Targets Immune Endocr. Metab. Disord., 5, 73-77. https://doi.org/10.2174/1568008053174732
  18. Wang, W., Chen, L., Zhou, R., Wang, X., Song, L., Huang, S., Wang, G. and Xia, B. (2014) Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrateproducing bacteria in inflammatory bowel disease. J. Clin. Microbiol., 52, 398-406. https://doi.org/10.1128/JCM.01500-13
  19. MacPherson, B.R. and Pfeiffer, C.J. (1978) Experimental production of diffuse colitis in rats. Digestion, 17, 135-150. https://doi.org/10.1159/000198104
  20. Strober, W., Fuss, I.J. and Blumberg, R.S. (2002) The immunology of mucosal models of inflammation. Annu. Rev. Immunol., 20, 495-549. https://doi.org/10.1146/annurev.immunol.20.100301.064816
  21. Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y. and Nakaya, R. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694-702.
  22. Hyun, E., Andrade-Gordon, P., Steinhoff, M. and Vergnolle, N. (2008) Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut, 57, 1222-1229. https://doi.org/10.1136/gut.2008.150722
  23. Baumgart, D.C. and Sandborn, W.J. (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 369, 1641-1657. https://doi.org/10.1016/S0140-6736(07)60751-X
  24. Cooper, H.S., Murthy, S.N., Shah, R.S. and Sedergran, D.J. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 69, 238-249.
  25. Hedger, M.P. and Meinhardt, A. (2003) Cytokines and the immune-testicular axis. J. Reprod. Immunol., 58, 1-26. https://doi.org/10.1016/S0165-0378(02)00060-8
  26. Eming, S.A., Kaufmann, J., Lohrer, R. and Krieg, T. (2007) [Chronic wounds. Novel approaches in research and therapy]. Hautarzt, 58, 939-944. https://doi.org/10.1007/s00105-007-1402-1
  27. Guha, M., O'Connell, M.A., Pawlinski, R., Hollis, A., McGovern, P., Yan, S.F., Stern, D. and Mackman, N. (2001) Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood, 98, 1429-1439. https://doi.org/10.1182/blood.V98.5.1429
  28. D'Aiuto, F., Parkar, M., Brett, P.M., Ready, D. and Tonetti, M.S. (2004) Gene polymorphisms in pro-inflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine, 28, 29-34. https://doi.org/10.1016/j.cyto.2004.06.005
  29. Cronstein, B.N. and Terkeltaub, R. (2006) Interleukin-6 and chronic inflammation. Arthritis Res. Ther., 8 Suppl 1, S3.
  30. Dieleman, L. and Hoentjen, F. (2012) [Probiotics have a limited role in the treatment of inflammatory bowel disease]. Ned. Tijdschr. Geneeskd., 156, A5206.

Cited by

  1. Grape seed extract improves epithelial structure and suppresses inflammation in ileum of IL-10-deficient mice vol.5, pp.10, 2014, https://doi.org/10.1039/C4FO00451E
  2. A 15-amino acid C-terminal peptide of beta-defensin-3 inhibits bone resorption by inhibiting the osteoclast differentiation and disrupting podosome belt formation vol.95, pp.12, 2017, https://doi.org/10.1007/s00109-017-1589-2
  3. Amelioration of obesity-related characteristics by a probiotic formulation in a high-fat diet-induced obese rat model pp.1436-6215, 2017, https://doi.org/10.1007/s00394-017-1481-4
  4. Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases vol.16, pp.9, 2015, https://doi.org/10.3390/ijms160920841
  5. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies vol.30, pp.1, 2017, https://doi.org/10.1128/CMR.00049-16
  6. The Probiotic, ID-JPL934, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice Through Inhibition of Proinflammatory Cytokines Expression vol.21, pp.9, 2018, https://doi.org/10.1089/jmf.2017.4152